Galmed Pharmaceuticals (GLMD) Change in Receivables (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Change in Receivables of $95000.0 for Q4 2025, up 9.2% year-over-year from $87000.0 in Q4 2024, and down 18.1% quarter-over-quarter from $116000.0 in Q3 2025.
Galmed Pharmaceuticals (GLMD) Change in Receivables (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Change in Receivables history runs 13 years deep, the most recent figure standing at $95000.0 for Q4 2025.
- In Q4 2025, Change in Receivables rose 9.2% year-over-year to $95000.0; the TTM figure through Dec 2025 stood at $589000.0 (up 13.93% YoY), while the FY2025 annual figure was -$28000.0, down 184.85% from the prior year.
- Change in Receivables for Q4 2025 stood at $95000.0, down from $116000.0 in the prior quarter.
- The five-year high for Change in Receivables was $1.2 million in Q4 2021, with the low at -$537000.0 in Q3 2021.
- The 5-year median for Change in Receivables is $41000.0 (2023), against an average of $41571.4.
- Peak annual rise in Change in Receivables reached 687.5% in 2021, while the deepest fall reached 256.56% in 2021.
- Galmed Pharmaceuticals' Change in Receivables stood at $1.2 million in 2021, then plunged by 123.32% to -$274000.0 in 2022, then slumped by 45.99% to -$400000.0 in 2023, then surged by 121.75% to $87000.0 in 2024, then gained by 9.2% to $95000.0 in 2025.
- Business Quant data shows GLMD's Change in Receivables at $95000.0 in Q4 2025, $116000.0 in Q3 2025, and $87000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | -104,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104,000.00 |
| Mar 31, 2026 | -104,000.00 |
| Dec 31, 2025 | 95,000.00 |
| Dec 31, 2025 | 95,000.00 |
| Sep 30, 2025 | 116,000.00 |
| Sep 30, 2025 | 116,000.00 |
| Dec 31, 2024 | 87,000.00 |
| Dec 31, 2024 | 87,000.00 |
| Sep 30, 2024 | 291,000.00 |
| Sep 30, 2024 | 291,000.00 |
| Dec 31, 2023 | -400,000.00 |
| Dec 31, 2023 | -400,000.00 |
| Sep 30, 2023 | 539,000.00 |
| Sep 30, 2023 | 539,000.00 |
| Jun 30, 2023 | -479,000.00 |
| Jun 30, 2023 | -479,000.00 |
| Mar 31, 2023 | -5,000.00 |
| Mar 31, 2023 | -5,000.00 |
| Dec 31, 2022 | -274,000.00 |
| Dec 31, 2022 | -274,000.00 |